| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | BDC-4182 (next-generation Boltbody™ ISAC) gastric cancer, gastroesophageal cancer | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
phase 1 data readout example | BDC-4182 (next-generation Boltbody™ ISAC) gastric cancer, gastroesophageal cancer | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
phase 1 data readout example | BDC-4182 (next-generation Boltbody™ ISAC) gastric cancer, gastroesophageal cancer | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Bolt Biotherapeutics, Inc.$3.99
+0.14 (+3.64%)
D 20Pipeline Score Richly Valued Pharma · Clinical
Market Cap
9.51 M
EPS
-16.34
P/E Ratio
-
Value Trade
117.73 K
SEC Financials
Q1 2026Dilution Risk
Revenue
26.00 K
R&D Expenses
4.83 M
Operating CF
-8.02 M
Total Assets
48.03 M
Total Liabilities
28.20 M
Equity
19.82 M
D/E Ratio
12,345
2.91 %
Week
-0.85 %
1 Month
-4.44 %
3 Month
2.48 %
6 Month
-98.71 %
5 Year
-99.05 %
All Time
Cash Data
Cash Position
22.89 M
Monthly Burn
2.67 M
Runway
7.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
39.57 K
52 Week Range
3.91 - 7.35
% held by Insiders
18.39 %
% held by Institutions
15.61 %
Enterprise Value
8.73 M
Total Shares
1.92 M
Short %
1.74 %
Float Shares
1.40 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D20
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 734 of 905)
Percentile RankBolt Biotherapeutics, Inc. faces pipeline headwinds (20/100), with $16M risk-adjusted pipeline value, led by BDC-4182 in Gastric Cancer Adenocarcinoma Metastatic (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDC-4182 Small molecule | Gastric Cancer Adenocarcinoma Metastatic | Phase 1 | NCT06921837 | 5% | $16M | RECRUITING | 122 | STALLED | D (33) | May 1, 2029 | VERY_HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BDC-3042 | non-small cell lung cancer | 1 | 2025-04-25 | |||
BDC-3042 | non-small cell lung cancer | 1 | 2025-04-25 | |||
BDC-3042 | non-small cell lung cancer | 1 | 2025-04-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BOLT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Bolt Biotherapeutics, Inc. (BOLT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BOLT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BOLT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BOLT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BOLT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BOLT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BOLTBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its first quarter 2026 financial results, highlighting the ongoing Phase 1/2 study of BDC-4182, an immune-stimulating antibody conjugate. The company has a cash balance of $23.9 million, expected to support operations into 2027. Initial clinical data from the study is anticipated in the third quarter of 2026. However, collaboration revenue has significantly decreased compared to the previous year.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its fourth quarter and full-year 2025 financial results, highlighting the promising early results of BDC-4182, a next-generation immune-stimulating antibody conjugate. The company is currently enrolling patients in a Phase 1 trial targeting gastric and gastroesophageal cancers, with initial data expected in Q3 2026. The report also emphasizes the innovative nature of the Boltbody ISAC platform in cancer treatment.
Read more →BOLTBolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics will participate in two conferences in March 2026, showcasing its commitment to advancing cancer treatments. The company is known for its innovative Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology, currently in clinical trials for gastric and gastroesophageal cancers. Additionally, Bolt is exploring partnerships for its Dectin-2 agonist and preclinical ISAC programs.
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics reported its third quarter 2025 financial results, highlighting its focus on the BDC-4182 Phase 1 dose-escalation study for gastric and gastroesophageal cancer. The company anticipates presenting initial data in the third quarter of 2026. With a cash runway extending into 2027, Bolt aims to create long-term shareholder value.
Read more →BOLTBolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics has provided an update on its Phase 1 study of BDC-4182, noting a strong immune response at initial dose levels. The company plans to modify the trial protocol for better dosing strategies and expects to report initial data in Q3 2026. However, to extend its cash runway into 2027, Bolt is reducing its workforce by about 50%.
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study • Cash balance of $48.5 mill
Bolt Biotherapeutics reported its financial results for Q2 2025, highlighting the initiation of a Phase 1 study for BDC-4182, targeting gastric and gastroesophageal cancer. The company has a robust cash balance of $48.5 million, expected to support key milestones through mid-2026. Despite the progress, the company faced a $9.2 million loss from operations and is looking for a partner for the further development of BDC-3042. Additionally, previous restructuring efforts have led to decreased expenses across various operational aspects.
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update • BDC-4182 Phase 1 dose-escalation study now open for enrollment • BDC-3042 Phase 1 dose-escalation data presen
Bolt Biotherapeutics has reported its first quarter 2025 financial results, highlighting advancements in its immunotherapy pipeline. The company has opened enrollment for the BDC-4182 Phase 1 study and presented encouraging data for BDC-3042, including favorable safety profiles. Collaboration revenue has decreased significantly, with a loss from operations reported at $12.1 million. The company maintains a cash balance of $58 million, which is projected to support operations through mid-2026.
Read more →BOLTBolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Bolt Biotherapeutics will host a KOL conference call on May 12, 2025, to discuss Phase 1 results of BDC-3042. Dr. Ecaterina Dumbrava from MD Anderson will present findings from the recent AACR Annual Meeting. The management team will also cover partnering plans and updates on BDC-4182 and financial results for Q1 2025.
Read more →BOLTBolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
Bolt Biotherapeutics presented promising preclinical results for its next-generation Boltbody ISACs targeting CEA and PD-L1 at the AACR Annual Meeting. The CEA-targeted ISAC showed complete and durable anti-tumor responses in mice and was well-tolerated in non-human primates. The PD-L1 ISAC demonstrated a novel mechanism of action, potentially enhancing cancer treatment strategies.
Read more →BOLTBolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics presented promising results from its Phase 1 study of BDC-3042 at the AACR Annual Meeting 2025. The drug showed a favorable safety profile and biological activity, with signs of anti-tumor effects in patients with non-small cell lung cancer. The company is seeking partners to advance the development of BDC-3042, which targets dectin-2 to activate immune responses.
Read more →BOLTBolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics has announced that it will present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the upcoming AACR Annual Meeting in April 2025. BDC-3042 is an innovative immunotherapy targeting dectin-2, aimed at treating patients with advanced solid tumors, including non-small cell lung cancer. Additionally, the company will share preclinical data on other projects, showcasing its commitment to advancing cancer treatments. The meeting serves as a platform for sharing significant findings in cancer research and treatment development.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update • BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 • BDC-304
Bolt Biotherapeutics has reported its fourth quarter and full-year financial results for 2024, highlighting significant advancements in its clinical pipeline. The company anticipates that BDC-4182 will enter clinical trials for gastric cancer by the second quarter of 2025. Additionally, the Phase 1 study of BDC-3042 is fully enrolled without any dose-limiting toxicities, and results will be reported in the same timeframe. Despite these positive developments, the company faced challenges with zero collaboration revenue this past quarter and a substantial loss from operations.
Read more →BOLTBolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
Bolt Biotherapeutics, Inc. has announced its collaboration with Toray Industries, Inc. to co-develop a cancer immunotherapy targeting Caprin-1, a novel antigen expressed in solid tumors. This partnership leverages Bolt's Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology alongside Toray's monoclonal antibody TRK-950, which is currently in Phase 2 trials for gastric cancer. The collaboration aims to enhance treatment options for patients with difficult-to-manage cancers while utilizing both companies' expertise in immunotherapy. This strategic alliance is seen as a significant step towards improving cancer care and outcomes.
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanc
Bolt Biotherapeutics reported its third quarter financial results for 2024, announcing progress in clinical trials for its cancer therapies BDC-3042 and BDC-4182. The company advanced to the highest dose level in the Phase 1 study of BDC-3042 and is preparing for clinical trials of BDC-4182, which is expected to begin in the second quarter of 2025. The firm reported a cash balance of $84.4 million, projected to support operations through mid-2026, although collaboration revenue showed a decrease from the previous year.
Read more →BOLTBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics presented updated preclinical data for BDC-4182 and insights from its Phase 1 dose-escalation trial of BDC-1001 at the SITC Annual Meeting. BDC-4182 exhibited strong anti-tumor activity and was shown to be safer compared to existing claudin 18.2 ADC treatments. Additionally, learnings from BDC-1001 support the hypothesis that improved immune activation in ISACs may lead to greater treatment efficacy. Clinical trials for BDC-4182 are anticipated to commence in 2025.
Read more →BOLTBolt Biotherapeutics Announces Changes to its Board of Directors
Bolt Biotherapeutics announced changes to its Board of Directors, appointing Jakob Dupont, M.D., as a new member. Dupont, who has extensive experience in oncology, replaces Dr. Jim Healy as Lead Independent Director, while Brian O’Callaghan takes over as Chair. The company is focused on advancing its clinical pipeline, specifically the Dectin-2 agonist and ISAC program targeting Claudin 18.2. The leadership changes are anticipated to strengthen the company as it works to improve cancer therapies.
Read more →BOLTBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Bolt Biotherapeutics, Inc. for alleged violations of securities laws. Investors who purchased securities from February 5, 2021, to May 14, 2024, are encouraged to participate in the lawsuit before the September 3, 2024 deadline. The company is accused of making false claims regarding its immune-stimulating antibody conjugate, BDC-1001, particularly in overestimating its effectiveness and commercial prospects. This has led to financial losses for shareholders as the truth about the company's performance has emerged.
Read more →BOLTBOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
Rosen Law Firm is urging investors of Bolt Biotherapeutics, Inc. to consider joining a class action lawsuit before the September 3, 2024 deadline. The lawsuit alleges that Bolt misrepresented the effectiveness of its product, BDC-1001, which was supposed to target HER2 cancer tumors but is claimed to be less effective than previously stated. This led to overstated expectations concerning Bolt's clinical and commercial prospects, exposing the company to risks of leadership turmoil and job cuts. Investors are encouraged to secure legal counsel as they navigate this situation.
Read more →BOLTBOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Bolt Biotherapeutics, Inc. The lawsuit seeks to recover damages for investors who acquired Bolt securities between February 5, 2021, and May 14, 2024. The complaint alleges that the company made materially false statements regarding the effectiveness of its product BDC-1001 and overestimated the commercial prospects of its pipeline. Investors are encouraged to join the lawsuit by visiting the law firm's website.
Read more →BOLTBolt Biotherapeutics to Participate in Upcoming September Conferences
Bolt Biotherapeutics has announced its participation in two significant upcoming conferences in September, including the Morgan Stanley 22nd Annual Global Healthcare Conference and H.C. Wainwright 26th Annual Global Investment Conference. The presentations will be accessible via webcast on the company's website with replays available for a limited duration. The company is focused on developing novel immunotherapies for cancer, with promising candidates in its pipeline currently undergoing clinical trials.
Read more →BOLTBOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
Rosen Law Firm is reminding investors of Bolt Biotherapeutics, Inc. about a key deadline in a Securities Class Action lawsuit regarding the company's performance and misleading statements. The suit claims that Bolt's product BDC-1001 was not performing as effectively as advertised, leading to overstated clinical and commercial prospects. Investors are encouraged to join the class action, with a deadline to serve as lead plaintiff set for September 3, 2024. The lawsuit highlights potential risks to Bolt's business model and investor confidence.
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers &#
Bolt Biotherapeutics has reported its financial results for the second quarter of 2024, highlighting significant progress in its clinical programs BDC-3042 and BDC-4182. The company has advanced to cohort 6 in the Phase 1 clinical trial of BDC-3042 targeting patients with advanced cancers and expects to commence clinical trials for BDC-4182 in 2025. The company maintains a strong cash position of $97.5 million, anticipated to fund its initiatives through mid-2026, despite an increase in operational losses and restructuring charges during the quarter.
Read more →BOLTBOLT Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Against Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. faces a class action lawsuit filed by a shareholder alleging that the company misrepresented the efficacy of its drug candidate BDC-1001. The lawsuit claims that Bolt overstated the product pipeline's prospects, leading to significant operational changes, including a 50% workforce reduction. Following the company's announcement of ceasing development on BDC-1001, stock analysts downgraded Bolt, contributing to a drastic fall in its share price. Shareholders are encouraged to take legal action by filing motions to participate in the lawsuit by September 3, 2024.
Read more →BOLTBOLT ALERT: Bragar Eagel & Squire, P.C. is Investigating Bolt Biotherapeutics, Inc. on Behalf of Bolt Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into Bolt Biotherapeutics, Inc. on behalf of its stockholders due to potential violations of federal securities laws. The investigation arises from claims that the company made materially false statements regarding its business operations and the effectiveness of its product BDC-1001. This situation raises concerns about the company's future, including possible workforce reductions and leadership changes. The law firm invites affected investors to reach out to learn more about their rights and potential claims.
Read more →BOLTBOLT Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Bolt Biotherapeutics, Inc.
A class action lawsuit has been filed against Bolt Biotherapeutics by investors who allege that the company misled them about the effectiveness of its drug candidate BDC-1001. The lawsuit comes after Bolt announced it would cease development of BDC-1001, citing that it did not meet the pre-defined success criteria. As part of this announcement, the company will also experience a significant leadership shift and workforce reduction, affecting around 50% of its staff. Analysts have since downgraded Bolt's stock, indicating skepticism regarding the commercial prospects of its remaining drug candidates BDC-3042 and BDC-4182.
Read more →BOLTBolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Bolt Biotherapeutics, Inc. regarding possible securities fraud, potentially leading to a class action on behalf of investors. This follows a significant announcement on May 14, 2024, where Bolt stated it would halt development of its lead asset and reduce its workforce by 50%. Consequently, Bolt's stock experienced a dramatic fall of over 37%, prompting analysts to downgrade the company's stock. Investors who have suffered losses are encouraged to contact the law firm for legal support.
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team • Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-gene
Bolt Biotherapeutics has reported its first-quarter 2024 financial results, highlighting a strategic pivot in its pipeline towards the Phase 1 program BDC-3042 and the next-generation Boltbody ISAC BDC-4182. The company plans to cease the development of BDC-1001 and has reduced its workforce significantly. Leadership changes were also announced, with Willie Quinn appointed as CEO. The company's financial position appears stable, with enough cash to sustain operations into the latter half of 2026.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward
Bolt Biotherapeutics has reported its financial results for Q4 and the full year 2023, highlighting significant progress in its clinical trials for BDC-1001 and BDC-3042. The company continues to advance its Phase 2 studies for trastuzumab imbotolimod in various HER2-positive tumor types, while the Phase 1 study for BDC-3042 showed no dose-limiting toxicities. As of December 31, 2023, Bolt's cash reserves stood at $128.6 million, providing a solid foundation to support ongoing and future clinical milestones into late 2025.
Read more →BOLTBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Bolt Biotherapeutics is set to present a company overview at the TD Cowen 44th Annual Healthcare Conference on March 5, 2024. The presentation will highlight the company’s innovative immunotherapies under development for cancer treatment, including its leading candidates, BDC-1001 and BDC-3042. BDC-1001 is in Phase 2 clinical development demonstrating early efficacy and tolerability, while BDC-3042 is poised to enter a Phase 1 trial later this year. The company's advancements underscore its commitment to improving cancer therapies.
Read more →BOLTBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu
Bolt Biotherapeutics announced the enrollment of the first patient in its Phase 2 clinical trial evaluating BDC-1001, an immunotherapy for HER2-positive breast cancer. This study aims to provide new treatment options for patients who have previously been treated with Enhertu. The trial will examine BDC-1001 both as a standalone treatment and in combination with the HER2-targeting antibody pertuzumab. A poster detailing the study's design will be presented at the upcoming 2023 San Antonio Breast Cancer Symposium.
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update – BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, e
Bolt Biotherapeutics has reported positive advancements in its BDC-1001 program, which is now undergoing multiple Phase 2 clinical studies for various HER2-positive cancers. The company recently presented updated efficacy data at the ESMO Congress, including a complete response observation. Additionally, BDC-1001 has received FDA Orphan Drug Designation for gastric cancer, potentially enhancing its development prospects. The company announced that it has begun dosing patients with BDC-3042, a new candidate under evaluation for multiple solid tumors. Financially, Bolt maintained a strong cash balance, expected to support further milestones until 2025.
Read more →BOLTBolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
Bolt Biotherapeutics will participate in the Stifel 2023 Healthcare Conference on November 14, 2023, presenting their advancements in immunotherapy for cancer treatment. The company focuses on teaching the immune system to recognize and combat cancer cells with personalized therapies. Notably, Bolt is developing two candidates currently in clinical trials: BDC-1001 and BDC-3042. A live webcast will be available for those wishing to follow the presentation online.
Read more →BOLTBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
Bolt Biotherapeutics presented updated clinical data on their investigational drug BDC-1001 at the ESMO 2023 Congress. The Phase 1 trial showed promising efficacy, including one complete response and improved disease control among HER2-positive tumor patients. BDC-1001 demonstrated a favorable safety profile, supporting the recommended Phase 2 dose. The company plans to advance to Phase 2 trials in various cancer types, with initial data expected in 2024.
Read more →BOLTBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
Bolt Biotherapeutics has announced its participation in the Society for Immunotherapy of Cancer's 38th Annual Meeting, where it will present four posters on its innovative immunotherapy research. Notable presentations include promising preclinical data on the combination of trastuzumab ISAC and pertuzumab, and the introduction of the Claudin 18.2 ISAC program. Additionally, the company will showcase trial-in-progress posters for its clinical candidates BDC-1001 and BDC-3042, highlighting its commitment to advancing cancer immunotherapy solutions.
Read more →BOLTBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
Bolt Biotherapeutics announced the dosing of the first patient in a Phase 1/2 study of BDC-3042, aimed at treating various advanced cancers. The trial will assess the safety and efficacy of BDC-3042, a novel Dectin-2 agonistic antibody targeting tumor-associated macrophages. This clinical trial could potentially pave the way for new treatment options for patients with conditions such as triple-negative breast cancer and non-small cell lung cancer. The company views this as an exciting advancement in its immunotherapy development pipeline.
Read more →BOLTBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
Bolt Biotherapeutics announced it will present updated clinical data from its completed Phase 1/2 trial of BDC-1001 at the ESMO Congress 2023. The investigational drug targets HER2-positive cancers and builds on previous positive findings presented at ASCO 2023. This upcoming presentation will offer new insights into the drug's efficacy, safety, and recommended Phase 2 dosing. BDC-1001 is currently undergoing further development in Phase 2 trials across various cancer types.
Read more →BOLTBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
Bolt Biotherapeutics has received Orphan Drug Designation from the FDA for its therapy BDC-1001, aimed at treating gastric cancers. This designation recognizes BDC-1001's potential to fulfill significant unmet medical needs in this patient population. The therapy is part of Bolt's ongoing efforts to develop immunotherapies targeting various types of cancers, with BDC-1001 currently in Phase 2 clinical trials in several regions. This designation also provides Bolt with potential advantages, such as market exclusivity post-approval and assistance in the drug development process.
Read more →BOLTBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
Bolt Biotherapeutics has announced the issuance of a foundational U.S. patent for BDC-3042, an agonist antibody targeting Dectin-2, which is poised to enter clinical trials this year. The patent, valid through May 2041, supports the company’s novel approach to converting tumor-associated macrophages into anti-tumor cells. This development highlights the potential of BDC-3042 as a promising candidate in cancer therapeutics due to its unique mechanism of action. The company continues to leverage its expertise in myeloid biology to advance its pipeline of immunotherapies.
Read more →BOLTBolt Biotherapeutics to Participate in September Investor Conferences
Bolt Biotherapeutics announced its participation in two key investor conferences in September: the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Global Investment Conference. The company will engage in discussions regarding its pipeline of cancer therapies, including the promising BDC-1001 and BDC-3042 candidates. A live webcast of the Morgan Stanley fireside chat will be available, with recordings accessible for 30 days post-event. This marks a proactive step in fostering investor relations and highlighting ongoing drug development efforts.
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update – First patients dosed in the BDC-1001 Phase 2 program – BDC-1001 Phase 1 data presented at ASCO 2023 demonstr
Bolt Biotherapeutics announced its second quarter 2023 financial results and provided an update on its clinical programs. The company has begun dosing patients in its BDC-1001 Phase 2 program and presented positive Phase 1 data at ASCO 2023, showcasing a favorable safety profile. Additionally, BDC-3042 received IND clearance, with trials expected to commence later this year. Despite the promising developments, the company reported a $19.8 million loss from operations.
Read more →BOLTBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
Bolt Biotherapeutics has initiated Phase 2 clinical trials for BDC-1001, an Immune-Stimulating Antibody Conjugate, targeting HER2-positive cancers. This milestone follows encouraging results from Phase 1 trials, indicating potential benefits for patients with colorectal, endometrial, and gastroesophageal cancers. The ongoing studies focus on evaluating the efficacy and safety of BDC-1001 as a monotherapy. This approach aims to address a significant need for effective treatments in the challenging landscape of HER2-positive tumor management.
Read more →BOLTBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
Bolt Biotherapeutics, a clinical-stage biopharma company, will present at the BTIG Virtual Biotechnology Conference 2023 on August 7, 2023. Management is set to engage in a fireside chat, showcasing their advancements in immuno-oncology therapeutics. The event will be accessible via a live webcast on Bolt's website, and archived presentations will be available for 30 days post-event. The company specializes in developing innovative therapies for cancer treatment, focusing on their lead candidates currently in clinical development.
Read more →BOLTBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Bolt Biotherapeutics announced promising data from its Phase 1 trial of BDC-1001, showing a 29% objective response rate in patients with HER2-positive tumors. The recommended Phase 2 dose was established at 20 mg/kg every two weeks. The trial demonstrated favorable safety and efficacy, leading to plans for a Phase 2 clinical program targeting four specific HER2-positive tumor types. The data underlines the potential of BDC-1001 as a new therapeutic modality in oncology.
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update – Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, includ
Bolt Biotherapeutics has reported its financial results for the first quarter of 2023 and provided a comprehensive business update. The company is advancing BDC-1001 into a Phase 2 program targeting multiple HER2-positive cancers after successful Phase 1 results, with a comprehensive dataset to be presented at ASCO 2023. Additionally, BDC-3042, an immune-activating antibody, is expected to enter clinical trials later this year. The company boasts a solid cash position of $171 million, helping to support its upcoming clinical milestones.
Read more →BOLTBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Bolt Biotherapeutics announced that it will present clinical data from its Phase 1 dose-escalation trial of BDC-1001 at the upcoming 2023 ASCO Annual Meeting. The investigational drug targets HER2-expressing tumors and the presentation will include results on safety and efficacy, which support the initiation of two Phase 2 trials. The company emphasizes its progress toward evaluating the drug's effectiveness both as a single agent and in combination with other therapeutic agents. Additionally, the Phase 2 studies will take place across the U.S., Europe, and South Korea.
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update – Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltb
Bolt Biotherapeutics has reported positive topline data from its BDC-1001 dose-escalation clinical study, validating its Boltbody ISAC platform's potential in generating anti-tumor activity. The company plans to advance BDC-1001 into a focused Phase 2 program in 2023 for multiple cancer types, alongside a second trial in breast cancer. Additionally, Bolt announced a collaboration with Roche for pertuzumab and mentioned plans to initiate BDC-3042 in the clinic later in 2023. Despite strong development updates, the company continues to report significant operational losses.
Read more →BOLTBolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
Bolt Biotherapeutics announced positive topline data from its Phase 1 dose-escalation study of BDC-1001, a treatment for HER2-expressing solid tumors. The data showed that BDC-1001 was well tolerated and resulted in objective clinical responses, including multiple partial responses, supporting its advancement into Phase 2 clinical studies. The company is expanding its Phase 2 program to evaluate BDC-1001 in combination with nivolumab and has formed a collaboration with Roche to assess the drug in conjunction with pertuzumab. Full results from the Phase 1 trial are expected to be shared at an upcoming medical conference.
Read more →BOLTBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
Bolt Biotherapeutics announced that it will present new preclinical data for BDC-3042, an agonistic antibody targeting Dectin-2, at the 2023 AACR Annual Meeting. The data highlights BDC-3042's potential to reprogram tumor-associated macrophages and enhance anti-tumor immunity. CEO Randall Schatzman expressed optimism for the antibody's clinical prospects in treating various cancers. The conference presentation is scheduled for April 17, 2023, at the Orange County Convention Center in Orlando, Florida.
Read more →BOLTBolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
Bolt Biotherapeutics is set to present an overview of its operations and pipeline at the Cowen 43rd Annual Healthcare Conference on March 7, 2023. The company specializes in developing novel immuno-oncology therapies for cancer treatment. It is currently progressing candidates such as BDC-1001 and BDC-3042 through various stages of clinical and preclinical trials. A live webcast of the presentation will be available, with archived replays provided for 30 days following the event.
Read more →BOLTBolt Biotherapeutics to Present at February Investor Conferences
Bolt Biotherapeutics will participate in two investor conferences in February 2023, including the Guggenheim Healthcare Talks and the SVB Securities Global Biopharma Conference. Management will engage in presentations and discussions about their cancer immuno-oncology therapeutics pipeline. This engagement highlights the company's ongoing commitment to inform and connect with investors regarding their clinical advancements. Live webcasts of these events will be available, offering further insights into their initiatives.
Read more →BOLTBolt Biotherapeutics Appoints Laura Berner to Board of Directors
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors ef
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update – BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 BDC-3042 on track to enter the clinic in 2023; new preclinical data at SITC 2022 Cash balanc
Read more →BOLTBolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical dat
Read more →BOLTBolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat a
Read more →BOLTBolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat a
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update – BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year New portfolio prioritization and capital allo
Read more →BOLTBolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-onc
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights – BDC-1001 monotherapy and OPDIVO combination trials progressing toward data readouts in second half of 2022  
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights BDC-1001 monotherapy and OPDIVO combination trials progressing toward data readouts in second half of 2022 Cash balance of $246.8 million expected to fund key milestones and opera
Read more →BOLTBolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and ada
Read more →BOLTBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights – BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended P
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study
Read more →BOLTBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and ada
Read more →BOLTBolt Biotherapeutics to Participate in Upcoming February Conferences
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive i
Read more →BOLTBolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adap
Read more →BOLTBolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive i
Read more →BOLTBolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 Company to continue monotherapy dose-e
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dos
Read more →BOLTBolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adap
Read more →BOLTBolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidate Demonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition with TLR
Read more →BOLTBolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights -BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights -BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 -Strong cash position of $2
Read more →BOLTBolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive i
Read more →BOLTBolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adap
Read more →BOLTBolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo for Treatment of HER2-Expressing Solid Tumors
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and ada
Read more →BOLTBolt Biotherapeutics to Participate in Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive
Read more →BOLTBolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs) Innovent will pay Bolt an upfront payment and fund development through clinical proof o
Read more →BOLTBolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights - BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021- - Announced R&D collabor
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights - BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021- - Announced R&D collaboration with Genmab to develop multiple bispecific ISACs for
Read more →BOLTBolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th cutoff date Monotherapy dose expansion and anti-PD-1 antibody combination parts of study expected to start in 2H 2021 REDWOOD CITY, Calif
Read more →BOLTGenmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration Media Release Collaboration to discover and evaluate novel product concepts based on the combination of Genmab's antibodies and bis
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration Copenhagen, Denmark and Redwood City, California; June 2, 2021 - Genmab A/S (Nasdaq: GMAB) and Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced today that the companies have entered into
Read more →BOLTBolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights - Strong cash position of $302.9 million as of
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights - Strong cash position of $302.9 million as of March 31, 2021 expected to deliver key value-creating milestones and fund operations into 2023 - - Upsized IPO in February 2021 rais
Read more →BOLTBolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
REDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and ada
Read more →BOLTBolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive
Read more →BOLTBolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights - Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business - Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million a total of $358 million in recent fundraising - Advanced first-in-cl
Read more →BOLTBolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock, inclusive of the full exercise by the
Read more →BOLTBolt Biotherapeutics Prices Upsized Initial Public Offering
REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00
Read more →Competitive Position
How BOLT ranks across every disease it competes inCompetitive Position is a premium feature
See how BOLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial